| EN

Simcere Announces Appointment of Dr. Danny Chen as Senior Vice President

Release time:2022-03-28


d19e82bd-2c4f-4551-8db7-8cd2aef39b7a.jpg

On March 28, 2022, Simcere Pharmaceutical Group (2096. HK) announces the appointment of Dr. Danny Chen as Senior Vice President of R&D. He will be responsible for translational science and the company’s central nervous system(CNS)pipeline, as well as building and leading the R&D team in Simcere’s Beijing Innovation Center.

 

"Welcome Dr. Danny Chen to join Simcere. He has over 20 years of experience in the pharmaceutical industry. His leadership in neuroscience and extensive expertise in R&D management will greatly reinforce our competitiveness in the field of CNS diseases, one of our strategically focused directions. We look forward to working with Dr. Danny Chen to create more innovative drugs with high clinical value." Said Mr. Jinsheng Ren, Chairman and CEO of Simcere

 

“I am very excited to join Simcere as the head of the Beijing Innovation Center and CNS development. Simcere's investment in innovative research and commitment to patient first drug development is truly inspirational. I look forward to establishing a center of excellence for translational research and a sustainable CNS research and development platform in Simcere. Our mission is to accelerate successful development of medicine for patients with unmet needs in China and globally. ” said Dr. Danny Chen.

 

Before joining Simcere, Dr. Danny Chen was the SVP of SciNeuro in charge of non-clinical and translational work. Prior to that, he had been worked in Pfizer (US) Neuroscience and Internal Medicine Research Unit for many years as clinical pharmacology head. Previously, he also served as the Principal Scientist at Purdue Pharma. Dr. Danny Chen has led multiple successful clinical development projects in the field of CNS diseases, and has profound experience in clinical translation, clinical development and registration, in- / out- licensing evaluation and partnering.

 

Danny Chen received his doctorate in pharmacy from Ohio State University and holds academic membership in the American Association of clinical pharmacology and Therapeutics, the American Conference on Pharmacometrics and the American Association of Medical Sciences.

 

 

About Simcere

 

Simcere Pharmaceutical Group is an innovation and R&D-driven pharmaceutical company with a mission of “providing today’s patients with medicines of the future.” It has established a National Key Laboratory of Translational Medicine and Innovative Drug Development. The company focuses on three therapeutic areas including oncology, central nervous system and autoimmune diseases with forward-looking layout of disease areas that may have significant clinical needs in the future. Based on the R&D and commercialization excellence, Simcere has built an industry-leading product portfolio. Its vigorous in-house R&D efforts and extensive R&D collaborations have made it a strategic cooperation partner with world leading innovative companies and research institutes.